Teadus Pharma

Executive Summary

Teadus Pharma is an Indian contract research and manufacturing organization (CRO/CDMO) specializing in custom chemical synthesis, peptide production, formulation development, and impurity profiling. Founded in 2020 and headquartered in Hyderabad, the company operates cGMP-compliant, USFDA-inspected facilities, offering end-to-end services from discovery to commercial manufacturing for pharmaceutical and biotech clients worldwide. With a growing focus on outsourcing of complex chemistries and peptide-based therapeutics, Teadus is positioned to capture demand from Western clients seeking cost-effective and high-quality alternatives. As a private company, financial performance is not publicly disclosed, but its USFDA-inspected status and comprehensive service portfolio provide a competitive edge in the fragmented CRO/CDMO market. The firm's early-stage yet operational profile suggests potential for steady growth through contract wins and facility expansions, though visibility remains limited due to lack of public disclosures.

Upcoming Catalysts (preview)

• Q3 2026USFDA Re-inspection or Approval of Additional Facilities70% success
• Q4 2026Announcement of Major Long-term Contract with Global Pharma50% success
• Q1 2027Launch of New Peptide Manufacturing Line or Expansion into New Therapeutic Areas60% success